ABSTRACT

Mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID) widely used for the treatment of menstrual cramps, has been banned in India due to its association with serious adverse drug reactions, particularly Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. This syndrome can result in severe health complications and poses significant risks to patients. Following the ban, a survey was conducted to assess the awareness and perceptions of healthcare providers and patients regarding the risks associated with mefenamic acid and the implications of its withdrawal from the market. The survey included responses from 300 participants, comprising physicians, gynecologists, and women who had previously used mefenamic acid. Results indicated that while a majority of healthcare providers were aware of the adverse effects associated with mefenamic acid, there was a notable gap in understanding DRESS syndrome specifically. Conversely, among patients, awareness of the drug's risks was alarmingly low, with many unaware of the reasons behind its ban. This analysis reveals critical insights into the knowledge disparities between healthcare professionals and patients regarding drug safety. The findings underscore the necessity for enhanced educational initiatives and clearer communication about the risks of medications, especially those commonly prescribed for prevalent conditions such as menstrual pain. The study emphasizes the need for alternative painmanagement strategies and highlights the importance of robust pharmacovigilance in safeguarding public health. Keywords: Mefenamic acid, Non-steroidal anti-inflammatory drug (NSAID), Menstrual cramps, Banned in India, Adverse drug reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, Survey, Pharmacovigilance
Publication date: 01/03/2026

https://ijbpas.com/pdf/2026/March/MS_IJBPAS_2026_9872.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.3.9872